Director at CalciMedica (CALC) granted stock options on 20,000 shares

Rhea-AI Filing Summary

CalciMedica, Inc. director Evgeny Zaytsev received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of $0.9654 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market trade. Following the grant, he holds options on 20,000 shares directly. According to the vesting terms, 1/36 of the options vest in equal monthly installments over three years from the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zaytsev Evgeny

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	20,000	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 20,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 20,000 options Exercise price: $0.9654 per share Expiration date: July 1, 2036 +1 more

4 metrics

Options granted 20,000 options Director stock option grant covering common shares

Exercise price $0.9654 per share Strike price for the 20,000 optioned shares

Expiration date July 1, 2036 Option term end for the director grant

Post-grant derivative holdings 20,000 options Total options held by Evgeny Zaytsev after transaction

Key Terms

Director Stock Option (Right to Buy), grant/award acquisition, vesting, underlying security

4 terms

Director Stock Option (Right to Buy) financial

"security title listed as "Director Stock Option (Right to Buy)""

grant/award acquisition financial

"transaction action described as "grant/award acquisition""

vesting financial

"1/36th of the shares subject to the option vest in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"underlying security title identified as Common Stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/07/2026 - 05:01 PM Accepted by SEC EDGAR 07/07/2026 - 05:00 PM Learn about SEC filing dates

FAQ

What did CalciMedica (CALC) director Evgeny Zaytsev report on this Form 4?

He reported receiving a grant of stock options for 20,000 shares of CalciMedica common stock. The filing shows this as a compensation-related award, not an open-market purchase or sale of existing shares.

What are the key terms of Evgeny Zaytsev’s CalciMedica stock options?

The options cover 20,000 underlying common shares at an exercise price of $0.9654 per share. They expire on July 1, 2036, giving a long exercise window tied to continued service and vesting.

How do the CalciMedica options granted to Evgeny Zaytsev vest over time?

The vesting schedule provides that 1/36 of the 20,000 optioned shares vest in equal monthly installments over three years after the grant date. This structure encourages ongoing board service during the vesting period.

Did Evgeny Zaytsev buy or sell CalciMedica (CALC) shares in the market?

No market trade was reported. The Form 4 shows a grant or award acquisition of derivative securities (stock options), with zero price per share at grant, rather than an open-market purchase or sale of common stock.

How many CalciMedica options does Evgeny Zaytsev hold after this transaction?

After the grant, he holds 20,000 stock options directly, each tied to one underlying share of CalciMedica common stock. This total reflects the awarded options reported in the Form 4 transaction table.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zaytsev Evgeny

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST S. BLVD, SUITE 300-9

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$0.9654	07/02/2026		A		20,000		(1)	07/01/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. 1/36th of the shares subject to the option vest in equal monthly installments over a three year period following the date of grant.

	/s/ John Dunn, Esq., Attorney-in-Fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)